Aim: While the majority of individuals with a first episode of psychosis (FEP) achieve symptomatic remission with the appropriate treatment, there is a small but significant proportion who do not achieve remission of symptoms despite adequate treatment with at least two antipsychotic medications (termed treatment resistance). Clozapine is indicated in individuals who fulfil the criteria for treatment-resistant schizophrenia, however, despite it being the most effective antipsychotic medication, there can be delays in the commencement of clozapine in eligible patients.
| INTRODUCTION
While the majority of individuals with a first episode of psychosis (FEP) achieve symptomatic remission with the appropriate treatment, there is a small but significant proportion who do not achieve full remission of symptoms with initial treatment (Edwards, Maude, McGorry, Harrigan, & Cocks, 1998) . A consensus definition of treatment-resistant schizophrenia has been developed and it is defined as a lack of satisfactory clinical response in psychotic symptoms to trials of two different antipsychotic medications with adequate duration, dose and adherence (Howes et al., 2017) . It is estimated that one-third of individuals diagnosed with schizophrenia experience prolonged and persistent positive psychotic symptoms and therefore can be classified as treatment-resistant (Lehman et al., 2004) .
Clozapine is the most effective antipsychotic medication for the treatment of positive psychotic symptoms (Leucht et al., 2009 (Leucht et al., , 2013 .
However, its use is limited as a third line medication in individuals with treatment-resistant schizophrenia due to its potentially fatal cardiac and haematological side effects. In addition to the superior effectiveness of clozapine in treating positive psychotic symptoms, longitudinal studies demonstrate better outcomes in terms of morbidity and mortality (Tiihonen et al., 2009) . Despite this evidence, it has been reported that clozapine is under-prescribed and underutilised (Goren et al., 2013) . It is estimated that the prevalence of treatment resistance is 16%-20% in those with a diagnosis of schizophrenia (Chakos, Lieberman, Hoffman, Bradford, & Sheitman, 2001; Mortimer, Singh, Shepherd, & Puthiryackal, 2010; Remington et al., 2013 ), yet the rate of clozapine prescription is as low as 2%-3% in the United States (Sernyak & Rosenheck, 2008) , 7% in Canada (Latimer et al., 2013), 19% in Australia (Malalagama, Bastiampillai, & Dhillon, 2011) and 20% in New Zealand (Dey, Menkes, Obertova, Chaudhuri, & Mellsop, 2016) . In the United Kingdom, it was reported that only 14%-50% of eligible patients were treated with clozapine (Stroup et al., 2009 ).
Despite its superior effectiveness and longer-term outcomes, it would appear that not all individuals with treatment-resistant schizophrenia receive a trial of clozapine.
This literature review aims to determine the delays in the initiation of clozapine in individuals with treatment-resistant schizophrenia and to examine barriers to the commencement of clozapine in eligible individuals.
| METHODS

| Inclusion and exclusion criteria
The inclusion criteria for this literature review were articles published in English that reported the time taken to commence clozapine in individuals deemed eligible according to any guidelines or defined criteria of treatment-resistant schizophrenia. Additionally, articles examining delays or barriers to the commencement of clozapine were included.
| Search strategy
The following search terms were entered into the MedLine database:
"first episode psychosis,", "psychosis," "psychotic," "schizophreni*," "early intervention," "factors," "delay," "commence," "start," "initiate,"
and "clozapine." The initial search generated 5588 articles and after a review of titles, 126 abstracts were identified and reviewed. Of these, 43 articles were reviewed in full and 18 fulfilled the inclusion criteria, 13 of which were related to the commencement of clozapine and five on the barriers to such delays. Additionally, reference lists of articles were reviewed for other eligible articles. The last search was conducted on July 7, 2017.
| Definitions
The mean theoretical delay in the commencement of clozapine was defined as the duration from the end of week six of the second antipsychotic trial to the initiation of clozapine. (Wheeler, 2008) . A total of 917 (32.8%) individuals were prescribed clozapine after a mean duration of illness of 9.7 years. The number of trials of antipsychotic medications prior to clozapine initiation was 3.5 and it was found that those who were younger, male and had a longer duration of illness were more likely to be prescribed clozapine.
In 2012, Howes et al. conducted a study involving 149 individuals who were prescribed clozapine and found that the mean time of delay to clozapine initiation was 47.7 months (Howes et al., 2012) . Furthermore, they found that the average number of adequate trials of antipsychotics prior to clozapine treatment was 2.8 and that polypharmacy was also a common practice. In the same year, Nielson et al. conducted a retrospective study including 633 individuals and the mean duration between diagnosis of a psychotic disorder to clozapine initiation was one to two years (Nielsen, Nielsen, & Correll, 2012) . The mean number of antipsychotic trials prior to clozapine initiation was 2.9, with 20.1% having had five or more antipsychotic trials and 13.7% with four trials. disorder and psychosis not otherwise specified (NOS) (Grover, Hazari, Chakrabarti, & Avasthi, 2015) . They found that the mean delay to the commencement of clozapine was 1.93 years and the mean number of adequate trials of antipsychotic medications was three. In addition, 27.5% of individuals received polypharmacy. In 2014 
| Barriers to the commencement of clozapine
A total of five studies were identified as being eligible on reporting barriers to the commencement of clozapine, one of these pertained to patients and four to clinicians. 
| Patient perspectives and barriers
| Clinician perspectives and barriers
Nielsen, Dahm, Lublin, and Taylor Studies in this review included individuals who were commenced on clozapine and retrospectively determined the delay, however, this method excludes individuals who were eligible for clozapine but never had a trial.
Hence, in addition to considering theoretical delays, it is important to consider those individuals who experienced a continual persistent "delay" as a result of never having had a trial of clozapine.
| Clinical implications
This review has highlighted a number of important clinical issues and it is likely that the significant delays identified in the commencement of clozapine will not be addressed unless there is a reform in both clinical services and attitudes of clinicians towards clozapine.
Early intervention for psychosis services have now been adopted worldwide, with over 200 services internationally (Jackson, 2009 
| Strengths and limitations
This literature review has a number of limitations. Firstly, we only included studies published in English and as a result, potentially missing studies from non-English speaking countries. This has particular relevance, as clozapine is one of the most commonly used antipsychotic medications in China, where it can be prescribed as a first line treatment (Y. L. Tang et al., 2008) . Additionally, we only searched one database, however, we used a broad search strategy and checked references in order to identify other eligible articles.
| CONCLUSION
The superiority of the effectiveness of clozapine is well-established, yet significant delays exist internationally in its commencement in those who would be eligible for a trial. Despite the limited studies, the indications are that clinicians' knowledge of and attitude to clozapine remain a more significant barrier to the commencement of clozapine in eligible patients. Education resources for clinicians as well as services specifically dedicated to early identification of eligible patients and management of their care thereafter would be beneficial in reducing the delays.
